Hanh, Author at Innovation and Value Initiative

PRESS RELEASE: IVI Convenes First-of-its-Kind Multi-Stakeholder Summit to Accelerate Aligning Value Assessment Methods with Real-World Decision Needs
PRESS RELEASE: IVI Convenes First-of-its-Kind Multi-Stakeholder Summit to Accelerate Aligning Value Assessment Methods with Real-World Decision Needs

IVI News, Press

PRESS RELEASE: IVI Convenes First-of-its-Kind Multi-Stakeholder Summit to Accelerate Aligning Value Assessment Methods with Real-World Decision Needs

Participants Define Consensus Expectations and Prioritize Research Agenda to Improve Value Assessment Methods Alexandria, VA – March 17, 2020 – The Innovation and Value Initiative (IVI), a research-based non-profit improving the science and practice of value assessment, recently hosted a first-of-its-kind multi-stakeholder summit to examine current gaps and emerging approaches in value assessment. The program [...]

Hanh2020-03-20T11:51:10-06:00March 17th, 2020|IVI News, Press|

The Ascendency of Value Assessment
The Ascendency of Value Assessment

IVI News, Viewpoints

The Ascendency of Value Assessment

Value assessment is a hot topic in healthcare. But how can it be improved so it's more relevant to answering the most important questions to patients, payers and providers? In this commentary, Jennifer Bright explains why we need data partners to catalyze improvement in value assessment. Read the article here.

Hanh2020-02-26T16:33:39-06:00February 7th, 2020|IVI News, Viewpoints|

PRESS RELEASE: Dr. Patricia Deverka Appointed as IVI’s First Chief Science Officer
PRESS RELEASE: Dr. Patricia Deverka Appointed as IVI’s First Chief Science Officer

IVI News, Press

PRESS RELEASE: Dr. Patricia Deverka Appointed as IVI’s First Chief Science Officer

IVI is thrilled to announce Pat Deverka, MD has joined our organization as our first Chief Science Officer. Dr. Deverka. Dr. Deverka brings to IVI more than three decades of experience in health economic research, public policy, patient engagement and program measurement across several academic, corporate and non-profit institutions. Read the full press release [...]

Hanh2020-02-03T12:45:09-06:00February 4th, 2020|IVI News, Press|

PRESS RELEASE: IVI Announces Six New Members to Board of Directors
PRESS RELEASE: IVI Announces Six New Members to Board of Directors

IVI News, Press

PRESS RELEASE: IVI Announces Six New Members to Board of Directors

IVI is pleased to announce the latest additions to our diverse and growing Board of Directors. Read the full press release here to learn who is helping us drive value assessment to the next level in 2020.

Hanh2020-01-31T13:23:10-06:00January 30th, 2020|IVI News, Press|

What’s in Store for 2020?
What’s in Store for 2020?

IVI News, Viewpoints

What’s in Store for 2020?

Jennifer Bright discusses the following three trends that began in 2019 and will pick up steam this year: Increased demand for value information for drugs; Increased number of voices asking whether value assessment is done the right way; and Momentum to improve value assessment models. Read the full article here. Please note that a Scrip [...]

Hanh2020-02-26T16:39:47-06:00January 9th, 2020|IVI News, Viewpoints|

IVI Unveils Updates to Rheumatoid Arthritis Model
IVI Unveils Updates to Rheumatoid Arthritis Model

IVI News

IVI Unveils Updates to Rheumatoid Arthritis Model

The Center for Biosimilars writes about IVI's recent updates to their IVI-RA value model to include biosimilars, triple therapy, Janus kinase (JAK) inhibitors, sarilumab, as well as updated treatment effect estimates based on additional randomized control trial (RCT) evidence, and updated cost estimates. Read the full article here.

Hanh2020-02-26T16:42:58-06:00January 8th, 2020|IVI News|

PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates
PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI News, Press

PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to [...]

Hanh2020-01-07T00:30:08-06:00January 7th, 2020|IVI News, Press|

Expanding Value Assessment Beyond Drugs
Expanding Value Assessment Beyond Drugs

IVI News, Viewpoints

Expanding Value Assessment Beyond Drugs

Jennifer Bright writes in Morning Consult that while we've made progress assessing the value of biopharmaceuticals, more focus is needed to develop bout transparent, patient-centered value assessment methods in healthcare technologies beyond drugs. Read the full article here.

Hanh2020-02-26T16:45:13-06:00December 19th, 2019|IVI News, Viewpoints|

PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors
PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors

IVI News, Press

PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors

As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? In the brief, the authors discuss how the failure of ICER’s analysis to evaluate [...]

Hanh2019-12-10T13:20:31-06:00December 10th, 2019|IVI News, Press|

IVI Showcases OSVP at HealthEconomics.com’s “Big Ideas Accelerating Change” Challenge
IVI Showcases OSVP at HealthEconomics.com’s “Big Ideas Accelerating Change” Challenge

IVI News

IVI Showcases OSVP at HealthEconomics.com’s “Big Ideas Accelerating Change” Challenge

As one of the nine finalists in HealthEconomics.com's inaugural challenge competition to accelerate change in health economics and outcomes research, IVI's Mark Linthicum offered a compelling case for how IVI's Open-Source Value Platform (OSVP) is catalyzing innovation to shake up value assessment. Mark's presentation, "Using Open-Source Models to Improve Value Assessment in the U.S.", outlined [...]

Hanh2019-12-05T15:26:31-06:00December 5th, 2019|IVI News|

About Hanh